GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CStone Pharmaceuticals (HKSE:02616) » Definitions » Total Current Assets

CStone Pharmaceuticals (HKSE:02616) Total Current Assets : HK$0.0 Mil (As of Jun. 2023)


View and export this data going back to 2019. Start your Free Trial

What is CStone Pharmaceuticals Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. CStone Pharmaceuticals's total current assets for the quarter that ended in Jun. 2023 was HK$0.0 Mil.


CStone Pharmaceuticals Total Current Assets Historical Data

The historical data trend for CStone Pharmaceuticals's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CStone Pharmaceuticals Total Current Assets Chart

CStone Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Current Assets
Get a 7-Day Free Trial 3,212.34 4,234.73 2,397.07 1,392.45 1,454.49

CStone Pharmaceuticals Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Total Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,397.07 1,848.25 1,392.45 - 1,454.49

CStone Pharmaceuticals Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

CStone Pharmaceuticals's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as

CStone Pharmaceuticals's Total Current Assets for the quarter that ended in Jun. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.


CStone Pharmaceuticals  (HKSE:02616) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

CStone Pharmaceuticals's Liquidation Value for the quarter that ended in Jun. 2023 is

Liquidation value
= Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=0-0+0.75 * 0+0.5 * 0
=0.0

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CStone Pharmaceuticals Total Current Assets Related Terms

Thank you for viewing the detailed overview of CStone Pharmaceuticals's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


CStone Pharmaceuticals (HKSE:02616) Business Description

Traded in Other Exchanges
Address
218 Xinghu Street, C1 Building, North Block, Suzhou Industrial Park, Shanghai, CHN, 215123
CStone Pharmaceuticals is engaged in the development and commercialization of innovative tumor immunotherapy and molecular-targeted drugs. It has been operating in one reportable segment, the research and development of complex biopharmaceutical products.
Executives
Su Zhou Gong Ye Yuan Qu Zheng Ze Yuan Shi Chuang Ye Tou Zi Qi Ye You Xian He Huo 2101 Beneficial owner
Su Zhou Gong Ye Yuan Qu Zheng Ze Ji Ming Gu Quan Tou Zi Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
Su Zhou Gong Ye Yuan Qu Zheng Ze Jian Kang Chuang Ye Tou Zi Guan Li Zhong Xin You Xian He Huo 2501 Other
Su Zhou Gong Ye Yuan Qu Yuan He Yuan Dian Chuang Ye Tou Zi Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
Su Zhou Gong Ye Yuan Qu Guan Wei Hui 2201 Interest of corporation controlled by you
Su Zhou Gong Ye Yuan Qu Jing Ji Fa Zhan You Xian Gong Si 2201 Interest of corporation controlled by you
Su Zhou Yuan He Kong Gu Gu Fen You Xian Gong Si 2201 Interest of corporation controlled by you
Fei Jianjiang 2201 Interest of corporation controlled by you
Wuxi Healthcare Ventures Ii, L.p. 2101 Beneficial owner
Wuxi Healthcare Management, Llc 2201 Interest of corporation controlled by you
Morgan Stanley 2201 Interest of corporation controlled by you
Gic Private Limited 2102 Investment manager
Jiang Frank Ningjun 2307 Founder of a discretionary trust who can infl
Graceful Beauty Limited 2101 Beneficial owner
Boyu Capital Holdings Ltd. 2201 Interest of corporation controlled by you

CStone Pharmaceuticals (HKSE:02616) Headlines

No Headlines